Pooled analysis of higher versus lower blood pressure targets for vasopressor therapy septic and vasodilatory shock

Intensive Care Medicine

Volumn 44, Issue 1, 2018, Pages 12-21

  Lamontagne, François ^a,b   Day, Andrew G ^c   Meade, Maureen O ^d,e   Cook, Deborah J ^d,e   Guyatt, Gordon H ^e   Hylands, Mathieu ^a   Radermacher, Peter ^f   Chrétien, Jean Marie ^g   Beaudoin, Nicolas ^a   Hébert, Paul ^h   D’Aragon, Frédérick ^a,b   Meziani, Ferhat ⁱ   Asfar, Pierre ^g  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^c KINGSTON GENERAL HOSPITAL   (Canada)

^d HAMILTON HEALTH SCIENCES   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f UNIVERSITY HOSPITAL ULM   (Germany)

^g ANGERS UNIVERSITY HOSPITAL   (France)

^h UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁱ HÔPITAL CIVIL   (France)

Author keywords

Critical care; Hypotension; Individual patient data meta analysis; Mean arterial blood pressure; Vasopressors

Indexed keywords

HYPERTENSIVE FACTOR; VASOCONSTRICTOR AGENT;

ALL CAUSE MORTALITY; CONGESTIVE HEART FAILURE; HUMAN; HYPERTENSION; HYPOTENSION; MEAN ARTERIAL PRESSURE; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT CODING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPTIC SHOCK; SYSTEMATIC REVIEW; TREATMENT DURATION; VASODILATATION; ADULT; BLOOD PRESSURE; MALE; QUALITY OF LIFE;

ADULT; BLOOD PRESSURE; HUMANS; HYPOTENSION; MALE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SHOCK, SEPTIC; VASOCONSTRICTOR AGENTS;

EID: 85038410433     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-017-5016-5     Document Type: Review

References (16)

1. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including the Pediatric S (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41:580–637
2. Cecconi M, De Backer D, Antonelli M, Beale R, Bakker J, Hofer C, Jaeschke R, Mebazaa A, Pinsky MR, Teboul JL, Vincent JL, Rhodes A (2014) Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med 40:1795–1815
3. Lamontagne F, Cohen D, Herridge M (2017) Understanding patient-centredness: contrasting expert versus patient perspectives on vasopressor therapy for shock. Intensive Care Med 43:1052–1054
4. Andreis DT, Singer M (2016) Catecholamines for inflammatory shock: a Jekyll-and-Hyde conundrum. Intensive Care Med 42:1387–1397
5. Asfar P, Meziani F, Hamel JF, Grelon F, Megarbane B, Anguel N, Mira JP, Dequin PF, Gergaud S, Weiss N, Legay F, Le Tulzo Y, Conrad M, Robert R, Gonzalez F, Guitton C, Tamion F, Tonnelier JM, Guezennec P, Van Der Linden T, Vieillard-Baron A, Mariotte E, Pradel G, Lesieur O, Ricard JD, Herve F, du Cheyron D, Guerin C, Mercat A, Teboul JL, Radermacher P, Investigators S (2014) High versus low blood-pressure target in patients with septic shock. N Engl J Med 370:1583–1593
6. Lamontagne F, Meade MO, Hebert PC, Asfar P, Lauzier F, Seely AJE, Day AG, Mehta S, Muscedere J, Bagshaw SM, Ferguson ND, Cook DJ, Kanji S, Turgeon AF, Herridge MS, Subramanian S, Lacroix J, Adhikari NKJ, Scales DC, Fox-Robichaud A, Skrobik Y, Whitlock RP, Green RS, Koo KKY, Tanguay T, Magder S, Heyland DK, Canadian Critical Care Trials G (2016) Higher versus lower blood pressure targets for vasopressor therapy in shock: a multicentre pilot randomized controlled trial. Intensive Care Med 42:542–550
7. Hylands M, Moller MH, Asfar P, Toma A, Frenette AJ, Beaudoin N, Belley-Cote E, D’Aragon F, Laake JH, Siemieniuk RA, Charbonney E, Lauzier F, Kwong J, Rochwerg B, Vandvik PO, Guyatt G, Lamontagne F (2017) A systematic review of vasopressor blood pressure targets in critically ill adults with hypotension. Can J Anaesth 64:703–715
8. Brown SM, Lanspa MJ, Jones JP, Kuttler KG, Li Y, Carlson R, Miller RR 3rd, Hirshberg EL, Grissom CK, Morris AH (2013) Survival after shock requiring high-dose vasopressor therapy. Chest 143:664–671
9. Briel M, Meade M, Mercat A, Brower RG, Talmor D, Walter SD, Slutsky AS, Pullenayegum E, Zhou Q, Cook D, Brochard L, Richard JC, Lamontagne F, Bhatnagar N, Stewart TE, Guyatt G (2010) Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. JAMA 303:865–873
10. Heyland DK, Muscedere J, Drover J, Jiang X, Day AG, Canadian Critical Care Trials G (2011) Persistent organ dysfunction plus death: a novel, composite outcome measure for critical care trials. Crit Care 15:R98
11. Guyatt GH, Busse JW (2016) Modification of cochrane tool to assess risk of bias in randomized trials. http://distillercer.com/resources/
12. Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D, Walter SD, Guyatt GH, Group S-S, Flynn DN, Elamin MB, Murad MH, Abu Elnour NO, Lampropulos JF, Sood A, Mullan RJ, Erwin PJ, Bankhead CR, Perera R, Ruiz Culebro C, You JJ, Mulla SM, Kaur J, Nerenberg KA, Schunemann H, Cook DJ, Lutz K, Ribic CM, Vale N, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Bucher HC, Nordmann AJ, Raatz H, da Silva SA, Tuche F, Strahm B, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Karanicolas PJ, Burns KE, Vandvik PO, Coto-Yglesias F, Chrispim PP, Ramsay T (2010) Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 303:1180–1187
13. Harrell FE (2001) Regression modeling strategies: with application to linear models, logistic regression and survival analysis. Springer, New York
14. van Buuren S (2007) Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res 16:219–242
15. Sun X, Ioannidis JP, Agoritsas T, Alba AC, Guyatt G (2014) How to use a subgroup analysis: users’ guide to the medical literature. JAMA 311:405–411
16. Walsh M, Srinathan SK, McAuley DF, Mrkobrada M, Levine O, Ribic C, Molnar AO, Dattani ND, Burke A, Guyatt G, Thabane L, Walter SD, Pogue J, Devereaux PJ (2014) The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index. J Clin Epidemiol 67:622–628